The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 24 March 2026•Updated 26 March 2026•

1 min read

Karyopharm Reports Mixed Results in Phase 3 SENTRY Trial for Myelofibrosis

Key Facts

1The Phase 3 SENTRY trial in myelofibrosis met its first co-primary endpoint of spleen volume reduction (SVR35).

2 months ago

Version History

3 additional sources confirmed this story

Version 12 months ago

What changed: Update includes details on the immaturity of survival data, the completion of a $30 million private placement, and a cash runway limited to Q2 2026 alongside persistent funding risks.

Karyopharm Therapeutics (KPTI) reported mixed Phase 3 SENTRY trial results for selinexor, meeting the spleen volume reduction endpoint but failing to improve total symptom scores. While the data showed a survival signal, the company noted that this signal is currently considered immature, adding to the regulatory uncertainty regarding FDA approval. On the financial front, the company completed a $30 million private placement to bolster its balance sheet. However, Karyopharm's cash runway now only extends into the second quarter of 2026, limiting its operational flexibility. Analysts highlight that the company faces persistent existential funding risks despite the recent financing. The company plans to engage with regulatory authorities to discuss the next steps for the development program amidst these complex clinical and financial conditions.